12 months ago
Hodgkin Lymphoma CAR-T Cell Therapy BRD-01 Clinical Trial Application Approved in China On July 10, 2024, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administrat...
12 months ago
FDA Yescarta (Axicabtagene Ciloleucel, Axi-Cel) Approval for Large B-Cell Lymphoma on April 1, 2022 On April 1, 2022, the FDA announced the approval of a new second-line treatment indication for Ax...
12 months ago
Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~ mRNA Vaccine Tumor immunotherapy, as ...
12 months ago
On May 27, 2022, FDA Tisagenlecleucel Accelerated Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma After ≥ 2 Lines of Systemic Therapy On May 27, 2022, the U.S. Food and Dru...
12 months ago
Why FDA Tecartus Suddenly Deleted the Warning Letter on January 23, 2024 After the FDA issued a safety labeling change notification to all commercial CAR-T therapy manufacturers, Tecartus received ...
12 months ago
On April 1, 2022, FDA Approved Yescarta for Second-line Treatment of Large B-cell Lymphoma On April 1, 2022, Kite, a subsidiary of Gilead Sciences, announced that the U.S. Food and Drug Administrat...
12 months ago
Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1% Gastric Cancer According to a report by People’s Daily on A...
12 months ago
###IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy IMWG ###EquecabtageneAutoleucel: Leading China’s CAR-T Therapy to Glob...
12 months ago
Approved Indications for EMA Yescarta Diffuse Large B-cell Lymphoma (DLBCL) and Advanced B-cell Lymphoma (HGBL) on October 17, 2022 On October 17, 2022, exciting news came from the European Commiss...
12 months ago
**Tumors Vanish After One Year of Treatment! The First Advanced #GastricCancer Patient to Receive the New #Cancer Vaccine Achieves Lasting Remission** Cancer Vaccine Mrs. Liu, who was battling ad...
12 months ago
EMA Tecartus (Brexucabtagene Autoleucel) Approved for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) on December 17, 2020 On December 17, 2020, Gilead’s subsidiary Kit...
12 months ago
Overview of EMA Kymriah (Tisagenlecleucel) Approval Introduction Kymriah (tisagenlecleucel), formerly known as CTL019, is a groundbreaking CAR-T cell therapy that has revolutionized the treatment l...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
